Physician profile
Thomas L Dahl
NPI 1619090370
$1,834.25
in general payments reported to CMS, 2019-2025
17 companies · $243 in 2025
The $243 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $60.33 · 2021: $135 · 2022: $479 · 2023: $304 · 2024: $431 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $952 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $951.75 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $261.71 | 2019-2025 | Argos, Clareon, Centurion |
| Biotissue Holdings INC. | $210.44 | 2022-2025 | |
| Abbvie INC. | $204.62 | 2022-2025 | Lumigan |
| Rxsight INC | $191.76 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Oyster Point Pharma, INC. | $186.78 | 2022-2025 | Tyrvaya |
| Johnson & Johnson Surgical Vision, INC. | $161.26 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $125.71 | 2021-2025 | Acthar |
| Tarsus Pharmaceuticals, INC. | $116.12 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $98.57 | 2019-2024 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $58.19 | 2020-2021 | |
| Carl Zeiss Meditec USA, INC. | $51.77 | 2023 | |
| Aerie Pharmaceuticals, INC. | $47.42 | 2019-2021 | |
| Carl Zeiss Meditec Cataract Technology INC. | $38.88 | 2022 | |
| Allergan, INC. | $28.72 | 2019-2022 | |
| Ocular Therapeutix, INC. | $20.30 | 2024 | Dextenza |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $16.44 | 2023 | Vyzulta |
| Omeros Corporation | $15.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Dahl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.